José Ramón González Juanatey-rekin lankidetzan egindako argitalpenak (29)

2023

  1. Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: The DAPA-MODA study

    European Journal of Heart Failure, Vol. 25, Núm. 8, pp. 1352-1360

  2. Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat

    Patient Preference and Adherence, Vol. 17, pp. 839-849

2022

  1. Challenges in managing patients with heart failure with reduced ejection fraction

    Revista Espanola de Cardiologia Suplementos, Vol. 22, Núm. SB, pp. 1-7

  2. Role of vericiguat in the overall etiopathogenesis of heart failure with reduced ejection fraction. Current position

    Revista Espanola de Cardiologia Suplementos, Vol. 22, Núm. SB, pp. 8-14

  3. Therapeutic approach to patients with heart failure with reduced ejection fraction. The role of vericiguat

    Revista Espanola de Cardiologia Suplementos, Vol. 22, Núm. SB, pp. 23-29

  4. Vericiguat in heart failure: from scientific evidence to clinical practice

    Revista Clinica Espanola

  5. Vericiguat: VICTORIA trial results

    Revista Espanola de Cardiologia Suplementos, Vol. 22, Núm. SB, pp. 15-22

2021

  1. A 3-Biomarker 2-Point-Based Risk Stratification Strategy in Acute Heart Failure

    Frontiers in Physiology, Vol. 12

  2. Lipid lowering treatment in patients with very high risk cardiovascular disease. Spanish Society of Cardiology Consensus Document for the use of PCSK9 inhibitors in clinical practice

    REC: CardioClinics, Vol. 56, Núm. 1, pp. 39-48

  3. Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

    Journal of the American College of Cardiology, Vol. 78, Núm. 5, pp. 421-433

  4. Tratamiento hipolipemiante en los pacientes con enfermedad cardiovascular de riesgo muy elevado. Documento de consenso SEC sobre las indicaciones de los iPCSK9 en la práctica clínica

    REC: CardioClinics, Vol. 56, Núm. 1, pp. 39-48

2020

  1. Prevalence, clinical profile and prognostic implications of interatrial block in patients admitted for heart failure

    REC: CardioClinics, Vol. 55, Núm. 3, pp. 155-164

2019

  1. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

    The Lancet, Vol. 394, Núm. 10204, pp. 1169-1180

2017

  1. Cardiovascular efficacy and safety of bococizumab in high-risk patients

    New England Journal of Medicine, Vol. 376, Núm. 16, pp. 1527-1539

  2. Evolocumab and clinical outcomes in patients with cardiovascular disease

    New England Journal of Medicine, Vol. 376, Núm. 18, pp. 1713-1722

2016

  1. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC

    European Journal of Heart Failure, Vol. 18, Núm. 8, pp. 891-975

  2. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure

    Revista Espanola de Cardiologia, Vol. 69, Núm. 12, pp. 1167.-1167.

  3. Comentarios a la guía ESC 2016 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica

    Revista Espanola de Cardiologia, Vol. 69, Núm. 12, pp. 1119-1125

  4. Quality markers in cardiology: Measures of outcomes and clinical practice - A perspective of the Spanish Society of Cardiology and of Thoracic and Cardiovascular Surgery

    European Heart Journal, Vol. 37, Núm. 1, pp. 12-23

2015

  1. 2014 ESC/ESA guidelines on non-cardiac surgery: Cardiovascular assessment and management

    Russian Journal of Cardiology, Vol. 124, Núm. 8, pp. 7-66